Man Group’s Day One Biopharmaceuticals DAWN Stock Holding History

Man Group’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.29M	Buy	200,000 +2,904	+1%	+$40.9K	0.01%	1229
2025 Q4	$1.84M	Buy	197,096 +105,278	+115%	+$880K	﹤0.01%	1477
2025 Q3	$647K	Buy	91,818 +34,956	+61%	+$241K	﹤0.01%	1790
2025 Q2	$370K	Buy	56,862 +17,950	+46%	+$123K	﹤0.01%	1915
2025 Q1	$309K	Buy	38,912 +26,113	+204%	+$281K	﹤0.01%	1926
2024 Q4	$162K	Buy	+12,799	New	+$178K	﹤0.01%	1898

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Man Group's DAWN Position: Q1 2026 in Review

Man Group increased its Day One Biopharmaceuticals (DAWN) stake by 1.5% in Q1 2026, buying an estimated $40.9K and bringing the position to 200,000 shares worth $4.29M. The position accounts for 0.01% of the portfolio, ranked #1229.

Man Group first reported a position in DAWN in Q4 2024 and has held it in 6 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

Man Group held 200,000 shares of Day One Biopharmaceuticals worth $4.29M as of Q1 2026.
Man Group bought 2,904 Day One Biopharmaceuticals shares in Q1 2026, an estimated $40.9K.
Day One Biopharmaceuticals made up 0.01% of Man Group's portfolio in Q1 2026, its #1229 holding.
Man Group first reported a position in Day One Biopharmaceuticals in Q4 2024 and has held it in 6 quarters since.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.